Related references
Note: Only part of the references are listed.Large-vessel vasculitis
Dan Pugh et al.
NATURE REVIEWS DISEASE PRIMERS (2022)
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Bernhard Hellmich et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Association between Takayasu arteritis and latent or active Mycobacterium tuberculosis infection: a systematic review
Ana Luisa S. Pedreira et al.
CLINICAL RHEUMATOLOGY (2020)
Relapsing cutaneous leishmaniasis in a patient requiring TNF-α-inhibitor Infliximab for Takayasu-arteritis: Case report and review of the literature
Melina Heinemann et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE (2020)
ROS-producing immature neutrophils in giant cell arteritis are linked to vascular pathologies
Lihui Wang et al.
JCI INSIGHT (2020)
Overall survival and mortality risk factors in Takayasu's arteritis: A multicenter study of 318 patients
Adrien Mirouse et al.
JOURNAL OF AUTOIMMUNITY (2019)
Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
Deninson Alejandro Vargas et al.
FRONTIERS IN PHARMACOLOGY (2019)
Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review
Nahid Maspi et al.
PATHOGENS AND GLOBAL HEALTH (2016)
Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe
P. Zanger et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria
Seza Ozen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Leishmania donovani Isolates with Antimony-Resistant but Not -Sensitive Phenotype Inhibit Sodium Antimony Gluconate-Induced Dendritic Cell Activation
Arun Kumar Haldar et al.
PLOS PATHOGENS (2010)
Share Paper
